hims & hers fda warning letter compounded semaglutide 2025 and Novo Nordisk Warn of GLP-1 Telehealth Compounding Take Down – What's Next? Drug compounders sue FDA over

The surge of interest largely comes from popular GLP-1 drugs used for diabetes and GLP-1 weight loss treatments

How to Safely Use Compounded Semaglutide Given the documented risks and recent FDA actions, patients using compounded semaglutide should take extra precautions: Essential Safety Steps: Work with your Care Team: Always obtain prescriptions from licensed healthcare providers familiar with GLP-1 medications Verify pharmacy credentials: Ensure the compounding pharmacy is state-licensed and preferably PCAB-accredited Request detailed information: Ask about ingredient sources, quality control processes, and batch testing Follow the medication guide: Carefully review all instructions for dosing and administration Monitor for adverse events: Report any unusual symptoms to your provider immediately Red Flags to Avoid: Online pharmacies advertising generic Ozempic or generic Wegovy (no generics exist) Products labeled for research purposes only Unusually low prices or no prescription required Lack of clear dosing instructions or concentration information Claims of oral tablets or nasal sprays (unproven delivery methods) Important Contraindications: Never use semaglutide if you have: Personal or family history of medullary thyroid carcinoma Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) History of diabetic retinopathy (requires monitoring) Severe kidney problems or gallbladder problems Pregnancy or planned pregnancy With the FDAs recent enforcement actions, finding legitimate sources for compounded semaglutide has become more challenging

These comprehensive metrics become steady reference points during slower phases of progress

Retatrutide is the agonist of GLP-1 receptor, GIP receptor, and glucagon (GCG) receptor, which can reduce body weight and improve blood glucose by subcutaneous injection once a week(Rosenstock et al 2023)